Triple

T23466130
Position Surface form Disambiguated ID Type / Status
Subject ClinicalTrials.gov E569106 entity
Predicate relatedTo P37 FINISHED
Object U.S. Food and Drug Administration Amendments Act of 2007 — NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: U.S. Food and Drug Administration Amendments Act of 2007 | Statement: [ClinicalTrials.gov, relatedTo, U.S. Food and Drug Administration Amendments Act of 2007]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: U.S. Food and Drug Administration Amendments Act of 2007
Context triple: [ClinicalTrials.gov, relatedTo, U.S. Food and Drug Administration Amendments Act of 2007]
  • A. Food and Drug Administration Amendments Act of 2007 chosen
    The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
  • B. Food and Drug Administration Safety and Innovation Act of 2012
    The Food and Drug Administration Safety and Innovation Act of 2012 is a U.S. federal law that reauthorized and expanded FDA user fee programs while enhancing the agency’s authority over drug and medical device safety, innovation, and supply chain oversight.
  • C. Food and Drug Administration Modernization Act of 1997
    The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
  • D. Biologics Price Competition and Innovation Act
    The Biologics Price Competition and Innovation Act is a U.S. law that created an abbreviated regulatory pathway for approval of biosimilar and interchangeable biological products to promote competition while balancing incentives for innovation.
  • E. Prescription Drug User Fee Act of 1992
    The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2458ebd808190b3298163132cfb0b completed April 17, 2026, 2:37 p.m.
NER Named-entity recognition batch_69f1a6faaf8c8190b4fd191c54e1acea completed April 29, 2026, 6:36 a.m.
Created at: April 17, 2026, 5:54 p.m.